MIAX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Not a good buy right now. MIAX is sitting just under near-term support with weakening momentum (bearish MACD, RSI ~40) and no proprietary buy signals today. While Wall Street price targets imply upside and options open interest skews bullish, the current tape suggests limited immediate upside and a higher chance of drifting lower before the next clear catalyst (earnings on 2026-02-11).
Price/levels: Last close 41.07, below S1 (41.265) and above S2 (40.30), meaning it’s in a fragile support zone. A clean rebound would likely need to reclaim the pivot near 42.827; resistance sits at 44.39 then 45.355. Momentum: MACD histogram is negative (-0.148) and expanding lower, signaling bearish momentum is building rather than stabilizing. RSI(6) ~40 is weak/neutral-to-bearish (not oversold enough to signal a high-confidence bounce). Trend structure: Moving averages are converging, which often precedes a larger move; given current momentum, the bias is slightly downward unless price quickly reclaims 42.83. Quant-like pattern read: Similar-candlestick analog suggests ~60% odds of mild downside (-0.89% next day; -2.35% next month), aligning with the bearish MACD.
reinforce a bullish medium-term narrative.
on 2026-02-11 after hours, with Street EPS estimate of 0.41—if delivered, it can re-rate sentiment.
Short-term options flow is cautious/bearish (volume put/call 1.25), suggesting near-term hedging pressure.
Latest quarter provided: 2025/Q3. Revenue grew strongly to 336.145M (+35.16% YoY), indicating solid top-line momentum. Margins improved (gross margin 32.5, +9.95% YoY). However, profitability is still negative in the snapshot: net income at -102.08M and EPS at -1.46 (both shown as large YoY improvements but still losses). The trend is improving, but the business hasn’t clearly translated growth into consistent earnings yet—making the next earnings report a key confirmation point.
Recent trend: Analysts have been raising price targets into/after the company’s early public-company period. Morgan Stanley raised PT to $48 (Overweight), Piper Sandler raised PT to $52 (Overweight), and Keefe Bruyette raised PT to $44 (Market Perform). Wall Street pros: Scarcity value/takeout narrative, strong volume/operating leverage potential, and belief consensus forward EPS may be too low. Wall Street cons: Valuation debate—Piper notes the stock trades at a premium to U.S. exchange peers on 2027 P/E (even if discounted on 2027 EV/EBITDA), meaning execution must remain strong to justify the premium. Influential trading check: Hedge funds neutral (no significant trend last quarter), insiders neutral (no significant trend last month). No recent Congress trading data available.
